Last reviewed · How we verify
TPX-100 200mg, Once weekly for 4 weeks — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
TPX-100 200mg, Once weekly for 4 weeks (TPX-100 200mg, Once weekly for 4 weeks) — OrthoTrophix, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TPX-100 200mg, Once weekly for 4 weeks TARGET | TPX-100 200mg, Once weekly for 4 weeks | OrthoTrophix, Inc | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TPX-100 200mg, Once weekly for 4 weeks CI watch — RSS
- TPX-100 200mg, Once weekly for 4 weeks CI watch — Atom
- TPX-100 200mg, Once weekly for 4 weeks CI watch — JSON
- TPX-100 200mg, Once weekly for 4 weeks alone — RSS
Cite this brief
Drug Landscape (2026). TPX-100 200mg, Once weekly for 4 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/tpx-100-200mg-once-weekly-for-4-weeks. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab